High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis

 

 Buy Article Permissions and Reprints

Summary

The in-hospital incidence of pulmonary embolism (PE) in patients undergoing elective joint arthroplasty who receive a minimum of 10 days of dalteparin prophylaxis is reported to be less than 1%. Recent clinical experience raised suspicion that the incidence of PE was significantly higher at our tertiary care institution. It was the objective of this study to determine the incidence of in-hospital PE and symptomatic deep-vein thrombosis following elective joint arthroplasty in patients who received a minimum of 10 days of dalteparin prophylaxis. Consecutive charts of patients who underwent elective joint arthroplasty at our institution between January 2008 and June 2008 were reviewed. Data on risk factors for venous thromboembolism, objectively documented venous thromboembolic events, and signs and symptoms of PE were abstracted. Patients who received concomitant warfarin in the postoperative period were excluded. The study population consisted of 437 knee arthroplasty and 246 hip arthroplasty patients. The incidence of in-hospital PE following knee arthroplasty and hip arthroplasty was 4.6% and 0.4%, respectively. One out of every 10 knee patients, and one out of every 20 hip patients underwent testing for pulmonary embolism. Pulmonary embolism was diagnosed a median of 3.5 days after knee arthroplasty. The incidence of in-hospital PE in knee arthroplasty patients who received dalteparin prophylaxis was significantly higher than expected. Potential explanations for this finding include poor efficacy of dalteparin started 12–24 hours postoperatively and/or a low threshold for ordering diagnostic imaging for PE. Studies to clarify these issues are needed.

• References

• 1 Douketis JD, Eikelboom JW, Quinlan DJ. et al. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002; 162: 1465-1471.
  CrossrefPubMedGoogle Scholar
• 2 Value of the ventilation/perfusion scan in acute pulmonary embolism.. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators. J Am Med Assoc 1990; 263: 2753-2759.
  CrossrefPubMedGoogle Scholar
• 3 Schiff RL, Kahn SR, Shrier I. et al. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis. Chest 2005; 128: 3364-3371.
  CrossrefPubMedGoogle Scholar
• 4 Eriksson BI, Bergqvist D, Kalebo P. et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-1447.
  CrossrefPubMedGoogle Scholar
• 5 Eriksson BI, Arfwidsson AC, Frison L. et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 2002; 87: 231-237.
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Clayton RA, Gaston P, Watts AC. et al. Thromboembolic disease after total knee replacement: experience of 5100 cases. Knee 2009; 16: 18-21.
  CrossrefPubMedGoogle Scholar
• 7 Parvizi J, Smith EB, Pulido L. et al. The rise in the incidence of pulmonary embolus after joint arthroplasty: is modern imaging to blame?. Clin Orthop Relat Res 2007; 463: 107-113.
  PubMedGoogle Scholar
• 8 Dahl OE, Andreassen G, Aspelin T. et al. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997; 77: 26-31.
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Foley M, Maslack MM, Rothman RH. et al. Pulmonary embolism after hip or knee replacement: postoperative changes on pulmonary scintigrams in asymptomatic patients. Radiology 1989; 172: 481-485.
  CrossrefPubMedGoogle Scholar
• 10 Lemos MJ, Sutton D, Hozack WJ. et al. Pulmonary embolism in total hip and knee arthroplasty. Risk factors in patients on warfarin prophylaxis and analysis of the prothrombin time as an indicator of warfarin’s prophylactic effect. Clin Orthop Relat Res 1992; 158-163.
  PubMedGoogle Scholar